[11C]Raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length

Annals of Neurology

Volumn 43, Issue 2, 1998, Pages 253-255

  Antonini, Angelo ^a,b,c   Leenders, Klaus L ^b,d   Eidelberg, David ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c Istituti Clinici di Perfezionamento   (Italy)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; RACLOPRIDE; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; SALICYLAMIDE DERIVATIVE;

ADULT; ARTICLE; BRAIN DEGENERATION; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DRUG RECEPTOR BINDING; HUMAN; HUNTINGTON CHOREA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; TRINUCLEOTIDE REPEAT; CAUDATE NUCLEUS; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CROSS-SECTIONAL STUDY; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED; PUTAMEN; REGRESSION ANALYSIS; SCINTISCANNING;

ADULT; CAUDATE NUCLEUS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DOPAMINE ANTAGONISTS; HETEROZYGOTE; HUMANS; HUNTINGTON DISEASE; MIDDLE AGED; PUTAMEN; RACLOPRIDE; RECEPTORS, DOPAMINE; REGRESSION ANALYSIS; SALICYLAMIDES; TOMOGRAPHY, EMISSION-COMPUTED; TRINUCLEOTIDE REPEATS;

EID: 0031594146     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430216     Document Type: Article

References (20)

1. Furtado S, Suchowersky O, Rewcastle NB, et al. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 1996;39:132-136
2. Penney JB, Vonsattel JP, MacDonald ME, et al. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692
3. Mazziotta JC, Phelps ME, Pahl JJ, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987;316:357-362
4. Young AB, Penney JB, Starosta-Rubinstein S, et al. Normal glucose metabolism in persons at risk for Huntington's disease. Arch Neurol 1987;44:254-257
5. Brandt J, Folstein SE, Wong DF, et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. J Neuropsychiatry Clin Neurosci 1990;2: 20-27
6. Grafton ST, Mazziotta JC, Pahl JJ, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992;49:1161-1167
7. Ichise M, Toyama H, Fornazzari L, et al. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med 1993;34: 1247-1281
8. Turjanski N, Weeks R, Dolan R, et al. Striatal dopamine D1 and D2 receptor binding in patients with Huntington's disease and other choreas: a PET study. Brain 1995;118:689-696
9. Weeks RA, Piccini P, Harding AE, Brooks DJ. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 1996;40:40-54
10. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119:2085-2095
11. Albin RI, Reiner A, Anderson KD, et al. Preferential loss of striatal projection neurons in presymptomatic Huntington's disease. Ann Neurol 1992;31:425-430
12. Antonini A, Schwarz J, Oertel WH, et al. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with PET and [11C]raclopride. Mov Disord 1997;12: 33-38
13. Vonsattel JP, Myres RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577
14. Antonini A, Leenders KL, Reist H, et al. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and [11C]raclopride. Arch Neurol 1993;50:474-480
15. Ilarioshkin SN, Igarashi S, Onodera O, et al. Trinucleotide repeat length and rate of progression of Huntington's disease. Ann Neurol 1994;36:630-635
16. Brandt J, Bylsma FW, Gross R, et al. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 1996;46:527-531
17. Gusella JF, Persichetti F, MacDonald ME. The genetic defect causing Huntington's disease: repeated in other contexts? Mol Med 1997;3:238-246
18. Feigin A, Kieburtz K, Como P, et al. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996;11:321-323
19. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997;41:160-165
20. Kurth MC, Kopyov OV, Jacques DB, et al. Safety of fetal tissue transplantation for Huntington's disease. Neurology 1997; 48(Suppl 3):138(Abstract)